10058-F4
Based on 56 publication(s) in Google Scholar
10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.90%
- No. CAS: 403811-55-2
- Fòrmula: C12H11NOS2
- Peso molecular:249.35
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) 10058-F4
More- Nature. 2024 Jun;630(8018):968-975. [Abstract]
- J Hematol Oncol. 2020 Feb 5;13(1):11. [Abstract]
- Mol Cancer. 2024 Jul 9;23(1):141. [Abstract]
- Cell Metab. 2025 Apr 1;37(4):903-919.e10. [Abstract]
- Mil Med Res. 2022 Sep 27;9(1):54. [Abstract]
- Nat Metab. 2021 Jul;3(7):923-939. [Abstract]
- Nat Commun. 2025 Feb 26;16(1):1986. [Abstract]
- Adv Sci (Weinh). 2026 Mar;13(17):e16996. [Abstract]
- Adv Sci (Weinh). 2025 Jan 30:e2413445. [Abstract]
- Adv Sci (Weinh). 2023 Apr;10(12):e2201164. [Abstract]
- J Adv Res. 2025 Dec 8:S2090-1232(25)00996-8. [Abstract]
- J Exp Clin Cancer Res. 2023 Jul 6;42(1):159. [Abstract]
- Sci Adv. 2025 Nov 28;11(48):eady1693. [Abstract]
- Redox Biol. 2023 Dec:68:102956. [Abstract]
- Mol Biomed. 2020 Dec 30;1(1):18. [Abstract]
- Cell Death Dis. 2024 Jun 17;15(6):422. [Abstract]
- Cell Death Dis. 2023 Jan 18;14(1):38. [Abstract]
- Cell Death Dis. 2022 Apr 12;13(4):338. [Abstract]
- Cell Death Dis. 2021 Mar 12;12(3):261. [Abstract]
- Cell Death Dis. 2020 Nov 15;11(11):982. [Abstract]
- Cell Death Dis. 2018 Feb 22;9(3):307. [Abstract]
- Genes Dis. 2026 Feb 14.
- Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):e2014457118. [Abstract]
- Phytomedicine. 2025 Oct:146:157098. [Abstract]
- Phytomedicine. 2021 Jan;80:153383. [Abstract]
- Biomed Pharmacother. 2024 Aug 16:179:117315. [Abstract]
- Oncogene. 2021 Apr;40(14):2581-2595. [Abstract]
- Oncogene. 2020 Apr;39(16):3354-3366. [Abstract]
- Cell Rep. 2023 Nov 18;42(12):113434. [Abstract]
- Cell Rep. 2023 Oct 20;42(10):113306. [Abstract]
- Antioxidants (Basel). 2026 Mar 25;15(4):413. [Abstract]
- Oncogenesis. 2020 Apr 29;9(4):42. [Abstract]
- Mol Ther Nucleic Acids. 2025 Dec 15.
- Front Immunol. 2022 Aug 8;13:943174. [Abstract]
- J Invest Dermatol. 2023 Feb;143(2):197-208.e6. [Abstract]
- Biochem Pharmacol. 2023 Dec:218:115934. [Abstract]
- Chem Biol Interact. 2024 Jan 5:387:110807. [Abstract]
- Mol Ther Oncolytics. 2020 Jun 24;18:282-294. [Abstract]
- Commun Biol. 2025 Apr 17;8(1):624. [Abstract]
- Int J Oncol. 2023 Jan;62(1):8. [Abstract]
- Mol Oncol. 2018 Dec;12(12):2191-2208 [Abstract]
- Cancers (Basel). 2023 Oct 15;15(20):4995. [Abstract]
- iScience. 2025 Jul 5;28(8):113060. [Abstract]
- Neurochem Int. 2020 Dec;141:104860. [Abstract]
- Cell Signal. 2024 Mar:115:111039. [Abstract]
- Bone. 2023 Mar:168:116648. [Abstract]
- J Immunol. 2025 Jun 1;214(6):1219-1235. [Abstract]
- Dev Comp Immunol. 2020 Jan;102:103487. [Abstract]
- Comp Biochem Physiol A Mol Integr Physiol. 2020 Apr;242:110636. [Abstract]
- Eur J Integr Med. 2025 Aug 28;78:102545.
- bioRxiv. 2026 May 22:2026.05.20.726663. [Abstract]
- bioRxiv. 2026 Feb 2.
- Res Sq. 2026 Feb 23.
- ASPET Discov. 2025 Sep 2.
- bioRxiv. 2024 Mar 13:2024.03.12.584316. [Abstract]
- Research Square Preprint. 2020 Aug.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
In Vivo Efficacy Study
-
RT-PCR
-
WB
Actividad biológica
10058-F4 inhibits growth of leukemic cells and dimerization of Myc and Max. 10058-F4 induces cell-cycle arrest and apoptosis of AML cells. 10058-F4 arrests AML cells at G0/G1 phase, downregulates c-Myc expression and upregulated CDK inhibitors, p21 and p27. Meanwhile, 10058-F4 induces apoptosis through activation of mitochondrial pathway shown by downregulation of Bcl-2, upregulation of Bax, release of cytoplasmic cytochrome C, and cleavage of caspase 3, 7, and 9. Furthermore, 10058-F4 also induces myeloid differentiation, possibly through activation of multiple transcription factors. Similarly, 10058-F4-induced apoptosis and differentiation could also be observed in primary AML cells[1].
10058-F4 decreases c-Myc protein levels, inhibites proliferation of HepG2 cells likely through upregulation of cyclin-dependent kinase (cdk) inhibitor, p21WAF1 and lowers intracellular levels of [alpha]-fetoprotein (AFP). Treatment with 10058-F4 also downregulates human telomerase reverse transcriptase (hTERT) at the transcriptional level. In addition to inhibiting the proliferation of HepG2 cells, 10058-F4 enhances sensitivity to conventional chemotherapeutic agents, doxorubicin, 5-fluorouracil (5-FU) and cisplatin[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 403811-55-2
-
Appearance Solid
-
Peso molecular 249.35
-
Fòrmula C12H11NOS2
-
Color Light yellow to yellow
-
SMILES
O=C1NC(S/C1=C/C2=CC=C(CC)C=C2)=S
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (56)
-
Journal Impact Factor
-
Most Recent
-
Nature
2024 Jun;630(8018):968-975. PMID: 38867043
10058-F4 purchased from MedChemExpress. Usage Cited in: Nature. 2024 Jun;630(8018):968-975. [Abstract]
Percent viability BMDMs stimulated with LPS (1ug/mL) and treated with c-Myc inhibitors (KJ Pyr 9 10ug/mL and 10058-F4 10ug/mL), mTOR inhibitor (Rapamycin 250 ng/mL), AMPK agonist (AICAR 2ug/mL) and NF-κB inhibitor (BMS-345541 1.2ug/mL) for 24 h.
-
J Hematol Oncol
CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. [Abstract]2020 Feb 5;13(1):11. PMID: 32024555
10058-F4 purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2020 Feb 5;13(1):11. [Abstract]
Effects of c-Myc antagonist 10058-F4 (5 μM) treatment on SOX9 mRNA and protein expression levels in CD73-overexpressing hepatocellular carcinoma cells.
-
Mol Cancer
A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression. [Abstract]2024 Jul 9;23(1):141. PMID: 38982480 -
Cell Metab
2025 Apr 1;37(4):903-919.e10. PMID: 39933514 -
Mil Med Res
Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability. [Abstract]2022 Sep 27;9(1):54. PMID: 36163081
10058-F4 purchased from MedChemExpress. Usage Cited in: Mil Med Res. 2022 Sep 27;9(1):54. [Abstract]
Representative Western blotting results of c-Myc, HDAC7, p21, p27 and Cyclin D1 in the EC109 and EC9706 cells with 10058-F4 (0-0.3 mM; 48 h) treatment.
-
Nat Metab
2021 Jul;3(7):923-939. PMID: 34211180
10058-F4 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Jul;3(7):923-939. [Abstract]
The levels of total GLP-1 and active GLP-1 in the culture medium of intestinal organoids isolated from Mycfl/+ mice fed a HFD for 2 weeks and treated with vehicle or 10058-F4 (40 μM; 24 h).
10058-F4 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Jul;3(7):923-939. [Abstract]
mRNA levels of indicated genes in the intestinal organoids isolated from Mycfl/+ mice fed a HFD for 2 weeks and treated with vehicle or 10058-F4(20 μM or 40 μM; 24 h).
-
Nat Commun
8q24 derived ZNF252P promotes tumorigenesis by driving phase separation to activate c-Myc mediated feedback loop. [Abstract]2025 Feb 26;16(1):1986. PMID: 40011431 -
Adv Sci (Weinh)
TRIM47 Regulates Energy Metabolism via Glycolytic Reprogramming to Drive Hepatocellular Carcinoma Progression and Represents an Efficient Therapeutic Target. [Abstract]2026 Mar;13(17):e16996. PMID: 41632101 -
Adv Sci (Weinh)
Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer. [Abstract]2025 Jan 30:e2413445. PMID: 39887933 -
Adv Sci (Weinh)
Glutamine Metabolism Underlies the Functional Similarity of T Cells between Nile Tilapia and Tetrapod. [Abstract]2023 Apr;10(12):e2201164. PMID: 36890649 -
J Adv Res
c-Myc-PANK3-EMT axis regulates the structure and function of intestinal barrier in ulcerative colitis. [Abstract]2025 Dec 8:S2090-1232(25)00996-8. PMID: 41371401 -
J Exp Clin Cancer Res
TRAF2 promotes M2-polarized tumor-associated macrophage infiltration, angiogenesis and cancer progression by inhibiting autophagy in clear cell renal cell carcinoma. [Abstract]2023 Jul 6;42(1):159. PMID: 37415241 -
Sci Adv
2025 Nov 28;11(48):eady1693. PMID: 41313781 -
Redox Biol
MIOX inhibits autophagy to regulate the ROS -driven inhibition of STAT3/c-Myc-mediated epithelial-mesenchymal transition in clear cell renal cell carcinoma. [Abstract]2023 Dec:68:102956. PMID: 37977044 -
Mol Biomed
GEF-independent Ran activation shifts a fraction of the protein to the cytoplasm and promotes cell proliferation. [Abstract]2020 Dec 30;1(1):18. PMID: 35006421 -
Cell Death Dis
TGF-β1 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m6A modification. [Abstract]2024 Jun 17;15(6):422. PMID: 38886389 -
Cell Death Dis
HDAC7/c-Myc signaling pathway promotes the proliferation and metastasis of choroidal melanoma cells. [Abstract]2023 Jan 18;14(1):38. PMID: 36653340 -
Cell Death Dis
Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage. [Abstract]2022 Apr 12;13(4):338. PMID: 35414060 -
Cell Death Dis
Overexpression of Annexin A2 promotes proliferation by forming a Glypican 1/c-Myc positive feedback loop: prognostic significance in human glioma. [Abstract]2021 Mar 12;12(3):261. PMID: 33712571 -
Cell Death Dis
A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors. [Abstract]2020 Nov 15;11(11):982. PMID: 33191401 -
Cell Death Dis
PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis. [Abstract]2018 Feb 22;9(3):307. PMID: 29472550
10058-F4 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 22;9(3):307. [Abstract]
ACHN cells are treated with or without 10058-F4 for 24 h. After the 24-h treatment, proteins are extracted. Immunoblotting assays are performed to analyse E-cadherin, N-cadherin, Vimentin, ZEB1, ZEB2, Snail1, Snail2, Twist, Smad2, Smad3, p-Smad2 and p-Smad3 protein levels. GAPDH is used as the loading control.
10058-F4 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 22;9(3):307. [Abstract]
786-O cells are treated with or without 10058-F4 for 24 h. After the 24-h treatment, proteins are extracted. Immunoblotting assays are performed to analyse E-cadherin, N-cadherin, Vimentin, ZEB1, ZEB2, Snail1, Snail2 , Twist, Smad2, Smad3, p-Smad2 and p-Smad3 protein levels. GAPDH is used as the loading control.
-
-
Proc Natl Acad Sci U S A
2021 Feb 16;118(7):e2014457118. PMID: 33568529 -
Phytomedicine
Flemiphilippinin A induces paraptosis in lung cancer cells via c-Myc-driven endoplasmic reticulum stress and CHOP-mediated mitochondrial dysfunction. [Abstract]2025 Oct:146:157098. PMID: 40716126 -
Phytomedicine
Antileukemic effect of caffeic acid 3,4-dihydroxyphenetyl ester. Evidences for its mechanisms of action. [Abstract]2021 Jan;80:153383. PMID: 33091855 -
Biomed Pharmacother
c-Myc-XRCC2-FOS axis promotes the proliferation and the resistance to Doxorubicin of NSCLC. [Abstract]2024 Aug 16:179:117315. PMID: 39153434 -
Oncogene
LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation. [Abstract]2021 Apr;40(14):2581-2595. PMID: 33686242 -
Oncogene
C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma. [Abstract]2020 Apr;39(16):3354-3366. PMID: 32103167 -
Cell Rep
SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer. [Abstract]2023 Nov 18;42(12):113434. PMID: 37980563 -
Cell Rep
CD226 maintains regulatory T cell phenotype stability and metabolism by the mTOR/Myc pathway under inflammatory conditions. [Abstract]2023 Oct 20;42(10):113306. PMID: 37864795 -
Antioxidants (Basel)
Alpha-Lipoic Acid Inhibits IFN-γ-Induced PD-L1 Expression in Prostate Cancer Cells and Enhances T-Cell-Mediated Anti-Tumor Cytotoxicity. [Abstract]2026 Mar 25;15(4):413. PMID: 42072056 -
Oncogenesis
ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis. [Abstract]2020 Apr 29;9(4):42. PMID: 32350243 -
-
Front Immunol
EST12 regulates Myc expression and enhances anti-mycobacterial inflammatory response via RACK1-JNK-AP1-Myc immune pathway. [Abstract]2022 Aug 8;13:943174. PMID: 36003390 -
J Invest Dermatol
CXCL12/CXCR4 Axis Drives the Chemotaxis and Differentiation of B Cells in Bullous Pemphigoid. [Abstract]2023 Feb;143(2):197-208.e6. PMID: 36075452 -
Biochem Pharmacol
Hydroquinone-selected chronic myelogenous leukemia cells are sensitive to chloroquine-induced cytotoxicity via MCL1 suppression and glycolysis inhibition. [Abstract]2023 Dec:218:115934. PMID: 37989415 -
Chem Biol Interact
Interfering TRIB3 protects the blood brain barrier through PI3K/Akt pathway to alleviate cerebral ischemia-reperfusion injury in diabetes mellitus mice. [Abstract]2024 Jan 5:387:110807. PMID: 37980971 -
Mol Ther Oncolytics
Insulin and Metformin Control Cell Proliferation by Regulating TDG-Mediated DNA Demethylation in Liver and Breast Cancer Cells. [Abstract]2020 Jun 24;18:282-294. PMID: 32728616 -
Commun Biol
2025 Apr 17;8(1):624. PMID: 40247055 -
Int J Oncol
Anti‑silencing function 1B promotes the progression of pancreatic cancer by activating c‑Myc. [Abstract]2023 Jan;62(1):8. PMID: 36416310 -
Mol Oncol
Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. [Abstract]2018 Dec;12(12):2191-2208 PMID: 30353671 -
Cancers (Basel)
A Combinatorial Regulatory Platform Determines Expression of RNA Polymerase III Subunit RPC7α (POLR3G) in Cancer. [Abstract]2023 Oct 15;15(20):4995. PMID: 37894362 -
iScience
TFAP2A enhances tumor stemness and promotes metastasis in pancreatic ductal adenocarcinoma. [Abstract]2025 Jul 5;28(8):113060. PMID: 40727938 -
Neurochem Int
IFN-γ regulates the transformation of microglia into dendritic-like cells via the ERK/c-myc signaling pathway during cerebral ischemia/reperfusion in mice. [Abstract]2020 Dec;141:104860. PMID: 33022312 -
Cell Signal
LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway. [Abstract]2024 Mar:115:111039. PMID: 38199599 -
Bone
HIF-1α mediates osteoclast-induced disuse osteoporosis via cytoophidia in the femur of mice. [Abstract]2023 Mar:168:116648. PMID: 36563716 -
J Immunol
2025 Jun 1;214(6):1219-1235. PMID: 40073091 -
Dev Comp Immunol
Molecular cloning and functional characterization of MYC transcription factor in pathogen-challenged Apostichopus japonicus. [Abstract]2020 Jan;102:103487. PMID: 31472172 -
Comp Biochem Physiol A Mol Integr Physiol
Osmoregulation by the myo-inositol biosynthesis pathway in turbot Scophthalmus maximus and its regulation by anabolite and c-Myc. [Abstract]2020 Apr;242:110636. PMID: 31846703 -
-
bioRxiv
Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells. [Abstract]2026 May 22:2026.05.20.726663. PMID: 42239313 -
-
-
-
bioRxiv
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. [Abstract]2024 Mar 13:2024.03.12.584316. PMID: 38903083 -
Solvente y solubilidad
DMSO : 50 mg/mL (200.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.83 mg/mL (3.33 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.83 mg/mL (3.33 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Cells, plated in 96-well plates (105/mL for cell lines and 5×105/mL for primary leukemic cells), are treated in triplicate with indicated concentrations of 10058-F4. At various time points, 20 μL 5 mg/mL MTT is added to each well. After incubation at 37°C for 3 hours, the MTT medium is removed and 100 μL DMSO lysis buffer is added. The number of viable cells is assessed by the percentage of absorbance of treated cells relative to that of solvent controls, using 570-nm wavelength on a spectrophotometer.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
C B-17 SCID mice bearing PC-3 human prostate tumor xenografts are stratified into the following groups: Control, vehicle control, positive control (docetaxel, 10 mg/kg), and 10058-F4 treatment (20 or 30 mg/kg/dose). Previous studies by us indicates that 30 mg/kg is the maximally tolerated dose of 10058-F4 on this schedule. Mice are treated i.v. daily for 5 days for 2 weeks, and body weights and tumor volumes are recorded twice weekly. In the second study, C B-17 SCID mice bearing DU145 human androgen-independent prostate cancer xenografts are stratified to similar treatment groups. Docetaxel serves as the positive control for both efficacy studies and is administered i.v. every 7 days for two doses of 10 mg/kg. Tumors are measured with calipers, and tumor volumes are calculated using the formula: TV= L×W2/2 where L is the largest diameter of the tumor and W is the smallest diameter perpendicular to L. Mice are followed for at least 1 week following the completion of the dosing so that tumor regrowth could be monitored.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Huang MJ, et al. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol. 2006 Nov;34(11):1480-9. [Content Brief]
[2]. Lin CP, et al. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs. 2007 Feb;18(2):161-70. [Content Brief]
[3]. Guo J, et al. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0104 mL | 20.0521 mL | 40.1043 mL | 100.2607 mL |
| 5 mM | 0.8021 mL | 4.0104 mL | 8.0209 mL | 20.0521 mL | |
| 10 mM | 0.4010 mL | 2.0052 mL | 4.0104 mL | 10.0261 mL | |
| 15 mM | 0.2674 mL | 1.3368 mL | 2.6736 mL | 6.6840 mL | |
| 20 mM | 0.2005 mL | 1.0026 mL | 2.0052 mL | 5.0130 mL | |
| 25 mM | 0.1604 mL | 0.8021 mL | 1.6042 mL | 4.0104 mL | |
| 30 mM | 0.1337 mL | 0.6684 mL | 1.3368 mL | 3.3420 mL | |
| 40 mM | 0.1003 mL | 0.5013 mL | 1.0026 mL | 2.5065 mL | |
| 50 mM | 0.0802 mL | 0.4010 mL | 0.8021 mL | 2.0052 mL | |
| 60 mM | 0.0668 mL | 0.3342 mL | 0.6684 mL | 1.6710 mL | |
| 80 mM | 0.0501 mL | 0.2507 mL | 0.5013 mL | 1.2533 mL | |
| 100 mM | 0.0401 mL | 0.2005 mL | 0.4010 mL | 1.0026 mL |
Powered by Bioz